# A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

> **NCT02158936** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 356 (actual)

## Conditions studied

- Thrombocytopaenia

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** Azacitidine
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02158936
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06-10
- **Primary completion:** 2016-04-30
- **Final completion:** 2016-04-30
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2017-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02158936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02158936, "A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02158936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*